The literature has demonstrated that PSMA has better sensitivity and specificity than conventional methods or choline PET for detecting tumor recurrence, especially in patients with low PSA levels (<1.0 ng/mL) 35,36. This evidence concerns the gene FOLH1 and neoplasm.